Holen Sie sich die Stockscreener-App
1.27
0.79%
0.01
Handel nachbörslich:
1.28
0.01
+0.79%
Schlusskurs vom Vortag:
$1.26
Offen:
$1.27
24-Stunden-Volumen:
223.53K
Relative Volume:
0.51
Marktkapitalisierung:
$76.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.86M
KGV:
-1.1339
EPS:
-1.12
Netto-Cashflow:
$-55.66M
1W Leistung:
-9.29%
1M Leistung:
-9.29%
6M Leistung:
-13.01%
1J Leistung:
-54.15%
1-Tages-Spanne:
$1.24
$1.312
1-Wochen-Bereich:
$1.1901
$1.50
52-Wochen-Spanne:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Firmenname
Acumen Pharmaceuticals Inc
Sektor
Branche
Telefon
925-368-8508
Adresse
427 PARK ST., CHARLOTTESVILLE
Vergleichen Sie ABOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.27 | 86.01M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-07-26 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-20 | Fortgesetzt | BofA Securities | Buy |
| 2023-05-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Eingeleitet | BTIG Research | Buy |
| 2022-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-07-26 | Eingeleitet | BofA Securities | Neutral |
| 2021-07-26 | Eingeleitet | Credit Suisse | Outperform |
| 2021-07-26 | Eingeleitet | Stifel | Buy |
| 2021-07-26 | Eingeleitet | UBS | Buy |
Alle ansehen
Acumen Pharmaceuticals Inc Aktie (ABOS) Neueste Nachrichten
Developing predictive dashboards with Acumen Pharmaceuticals Inc. dataQuarterly Portfolio Review & AI Driven Price Predictions - Newser
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2025 Earnings Call Transcript - Insider Monkey
What’s the recovery path for long term holders of Acumen Pharmaceuticals Inc.2025 Earnings Surprises & Technical Buy Zone Confirmations - Newser
Advanced analytics toolkit walkthrough for Acumen Pharmaceuticals Inc.2025 Market Sentiment & Consistent Income Trade Ideas - Newser
Will Acumen Pharmaceuticals Inc. price bounce be sustainableRisk Management & Real-Time Volume Analysis Alerts - Newser
What institutional flow reveals about Acumen Pharmaceuticals Inc.Weekly Profit Analysis & Technical Confirmation Alerts - Newser
Can machine learning forecast Acumen Pharmaceuticals Inc. recoveryMarket Sentiment Summary & Daily Profit Focused Screening - Newser
Key metrics from Acumen Pharmaceuticals Inc.’s quarterly dataSwing Trade Picks with High Potential - Newser
Acumen Pharmaceuticals’ Q2 2025 Financial and Strategic Update - TipRanks
Using economic indicators to assess Acumen Pharmaceuticals Inc. potentialFree Low Volatility Stable Growth Picks - Newser
How to build a dashboard for Acumen Pharmaceuticals Inc. stockShort Squeeze Opportunities with Indicators - Newser
Acumen Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Acumen Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals (ABOS): A High-Conviction Play in the Next-Generation Alzheimer's Therapies - AInvest
Acumen Pharmaceuticals' Q2 2025: Key Contradictions in Alzheimer's Biomarker Strategies and Treatment Approaches - AInvest
Is Acumen Pharmaceuticals Inc. stock entering bullish territoryFree Target Return Focused Trade Insights - Newser
Will Acumen Pharmaceuticals Inc. benefit from macro trendsMarket Downturn Defense Strategy Analysis - Newser
Transcript : Acumen Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Earnings call transcript: Acumen Pharmaceuticals Q2 2025 sees EPS miss and stock dip - Investing.com
Acumen Pharmaceuticals Q2 net loss widens - MarketScreener
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
Acumen Reports Strong $166M Cash Position, Cuts Alzheimer's Trial Costs 40% with Innovation - Stock Titan
Using data tools to time your Acumen Pharmaceuticals Inc. exitLow Risk High Confidence Watchlist Builder - Newser
Can Acumen Pharmaceuticals Inc. sustain its profitabilityNext Day Profit Stock Signals - classian.co.kr
Analyzing drawdowns of Acumen Pharmaceuticals Inc. with statistical toolsAlgorithmic Forecast for Swing Trading Picks - Newser
What makes Acumen Pharmaceuticals Inc. stock price move sharplyFree Low Risk Equity Screener With Results - Newser
Using Python tools to backtest Acumen Pharmaceuticals Inc. strategiesHigh Confidence Strategy with Trend Alignment - Newser
What’s next for Acumen Pharmaceuticals Inc. stock priceFree Low Risk Picks for Daily Trading - Newser
Earnings visualization tools for Acumen Pharmaceuticals Inc.Weekly Stock Market Strategy Summary - Newser
Acumen Pharmaceuticals Inc. stock momentum explainedTrade Safety Matrix for Conservative Traders - Newser
Acumen Pharmaceuticals Inc. Building a Base Near SupportAI Powered High Return Stock Calls Dominate Watchlists - beatles.ru
Acumen Pharmaceuticals (ABOS) Projected to Post Quarterly Earnings on Tuesday - Defense World
Evaluating Acumen Pharmaceuticals Inc. with trendline analysisFree Triple Digit Growth Focused Trade Plan - Newser
How Acumen Pharmaceuticals Inc. stock performs during market volatilityDaily Market Movers Screener with Filters - Newser
Finanzdaten der Acumen Pharmaceuticals Inc-Aktie (ABOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Acumen Pharmaceuticals Inc-Aktie (ABOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):